Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780917 | 0.92 | CDK1 (0.48) | CDK1PDE5AAPPPDE4APDE4B | |
| SCHEMBL5828183 | 0.89 | CCNE2 (0.52) | CDK1PDE5AAPPTMIGD3HTR2C | |
| SCHEMBL14181335 | 0.88 | CDK1 (0.47) | CDK1PDE5AAPPPDE4APDE4B | |
| SCHEMBL20119583 | 0.87 | TMIGD3 (0.43) | CDK1PDE5AAPPPDE4APDE4B | |
| SCHEMBL19459471 | 0.87 | TMIGD3 (0.68) | TMIGD3HTR2CHTR2B | |
| SCHEMBL30141144 | 0.87 | TMIGD3 (0.68) | TMIGD3HTR2CHTR2B | |
| SCHEMBL26784724 | 0.86 | CCNE2 (0.44) | CDK1PDE5AAPPPDE4APDE4B | |
| SCHEMBL3852234 | 0.85 | KDM4C (0.49) | CDK1PDE5ATMIGD3HTR2CHTR2B | |
| SCHEMBL19799154 | 0.84 | TMIGD3 (0.53) | CDK1APPTMIGD3HTR2CHTR2B | |
| SCHEMBL7075104 | 0.84 | TMIGD3 (0.53) | TMIGD3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| CN-113444113-A | Artemisinin-base split compound or pharmaceutically acceptable salt thereof, pharmaceutical preparation and application | 贵州大学 | 2021-09-28 | — | — | CN | disclosed |
| EP-3786164-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | Ting Therapeutics LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3310783-B1 | COMPOSITIONS FOR THE PREVENTION OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020186220-A1 | COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2020-09-17 | — | — | WO | disclosed |
| US-20200179397-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2020-06-11 | — | — | US | disclosed |
| US-6703395-B2 | ADMINISTERING2-(((3-HYDROXYPROPYL)AMINO)-6-BENZYLAMINO)-9 -ISOPROPYLPURINE OR ITS SALT FOR THERAPY OF LEUKEMIA | INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2004-03-09 | — | — | US | disclosed |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2003-10-02 | — | — | US | disclosed |
| EP-1308447-A1 | Purine derivatives having antiproliferative properties and biological uses thereof | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2003-05-07 | — | — | EP | disclosed |
| EP-0874847-B1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2003-03-19 | — | — | EP | disclosed |
| US-20020065293-A1 | Cyclin dependent kinase inhibitor | INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC | 2002-05-30 | — | — | US | disclosed |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2002-04-25 | — | — | US | disclosed |
| US-6316456-B1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-11-13 | — | — | US | disclosed |
| US-6221873-B1 | CONTACTING SAID CELL WITH A COMPOUND 2-(HYDROXYALKYLAMINO)-6-BENZYLAMINO-9-ISOPROPYLPURINE; CDK4 CDK7 ENZYMES ARE INHIBITED IN SAID CELL. | INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2001-04-24 | — | — | US | disclosed |
| EP-0874847-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020842-A1 | NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000881-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | CDK1 6/4885PDE5A 1660/4885APP 1395/4885 |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | CDK1 3328/4885PDE5A 459/4885APP 2138/4885 |
| US-20200179397-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | CDK2, CDK5, CDK20 | CDK1 6/4885PDE5A 1660/4885APP 1395/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | CDK1 2235/4885PDE5A 566/4885APP 1642/4885 |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885PDE5A 680/4885APP 2732/4885 |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885PDE5A 680/4885APP 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.